Source-grounded facts extracted from Armata Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Armata Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: revenue $1.3 million, net income $(8.6) million.
“Third Quarter 2022 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.3 million for the three months ended September 30, 2022, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of Staphylococcus aureus bacteremia. The Company expects to receive $16.3 million in grant funding from MTEC administered by the U.S. Department of Defense and the Defense Health Agency and Joint Warfighter Medical Research Program. The Company recognized approximately $1.3 million of revenue in the comparable period in 2021. Research and Development. Research and development expenses for the three months ended September 30, 2022, were approximately $8.4 million as compared to approximately $5.6 million for the comparable period in 2021. The company continues to invest in clinical trial and personnel related expenses associated with its primary development programs. General an”
Erin Butler was appointed as Vice President of Finance and Administration and Principal Financial and Accounting Officer at Armata Pharmaceuticals, Inc..
“On March 25, 2022, the Board appointed Erin Butler to serve as (i) Vice President of Finance and Administration of the Company, effective April 1, 2022, and (ii) Principal Financial and Accounting Officer of the Company, effective July 1, 2022.”
Steve R. Martin departed as Chief Financial Officer and Senior Vice President at Armata Pharmaceuticals, Inc..
“On March 25, 2022, Steve R. Martin notified Armata Pharmaceuticals, Inc. (the “Company”) that he intends to retire as Chief Financial Officer and Senior Vice President (and Principal Financial and Accounting Officer) of the Company effective as of June 30, 2022 (the “Transition Date”).”
Todd R. Patrick resigned as Chief Executive Officer at Armata Pharmaceuticals, Inc..
“Todd R. Patrick, who has served as the Company’s CEO since May 2019, resigned as CEO as of August 1, 2021”
Brian Varnum was appointed as Chief Executive Officer at Armata Pharmaceuticals, Inc..
“On August 1, 2021, Brian Varnum, Ph.D. was appointed to serve as Chief Executive Officer”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.